Review



sci darapladib group  (TargetMol)


Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    TargetMol sci darapladib group
    Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the <t>SCI</t> and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with <t>Darapladib</t> (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.
    Sci Darapladib Group, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sci darapladib group/product/TargetMol
    Average 93 stars, based on 3 article reviews
    sci darapladib group - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Inhibiting ceramide synthase 5 expression in microglia decreases neuroinflammation after spinal cord injury"

    Article Title: Inhibiting ceramide synthase 5 expression in microglia decreases neuroinflammation after spinal cord injury

    Journal: Neural Regeneration Research

    doi: 10.4103/nrr.nrr-d-23-01933

    Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the SCI and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with Darapladib (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.
    Figure Legend Snippet: Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the SCI and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with Darapladib (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Immunofluorescence, Staining, Comparison, Binding Assay

    Figure 8 ｜Darapladib inhibits microglial pyroptosis in the spinal cord after SCI. (A) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells in the SCI and Sham groups after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the SCI + Darapladib group compared with the SCI and SCI + Vehicle groups. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bars: 100 μm (upper); 20 μm (lower). (B) Western blot analysis of the expression levels of Pla2g7 and proteins associated with the classical NLRP3 pyroptosis pathway in the SCI and Sham groups after treatment with Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, vs. SCI group (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-term gasdermin D; IL: interleukin; NLRP3: NOD-like receptor thermal protein domain associated protein 3; Pla2g7: phospholipase a2 group VII; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.
    Figure Legend Snippet: Figure 8 ｜Darapladib inhibits microglial pyroptosis in the spinal cord after SCI. (A) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells in the SCI and Sham groups after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the SCI + Darapladib group compared with the SCI and SCI + Vehicle groups. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bars: 100 μm (upper); 20 μm (lower). (B) Western blot analysis of the expression levels of Pla2g7 and proteins associated with the classical NLRP3 pyroptosis pathway in the SCI and Sham groups after treatment with Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, vs. SCI group (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-term gasdermin D; IL: interleukin; NLRP3: NOD-like receptor thermal protein domain associated protein 3; Pla2g7: phospholipase a2 group VII; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Techniques Used: Immunofluorescence, Staining, Western Blot, Expressing, Comparison



    Similar Products

    sci darapladib group  (TargetMol)
    93
    TargetMol sci darapladib group
    Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the <t>SCI</t> and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with <t>Darapladib</t> (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.
    Sci Darapladib Group, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sci darapladib group/product/TargetMol
    Average 93 stars, based on 1 article reviews
    sci darapladib group - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the SCI and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with Darapladib (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Journal: Neural Regeneration Research

    Article Title: Inhibiting ceramide synthase 5 expression in microglia decreases neuroinflammation after spinal cord injury

    doi: 10.4103/nrr.nrr-d-23-01933

    Figure Lengend Snippet: Figure 7 ｜Pla2g7 is essential for mediating the regulatory effects of CerS5 on pyroptosis. (A) Ceramide concentrations in the spinal cord in the SCI and Sham groups were detected by ELISA, and the data were normalized to the Shame group (n = 3). (B) Western blot analysis of Pla2g7, p50, GSDMD, and GSDMD-N expression levels in BV2 cells after treatment with Darapladib (Pla2g7 inhibitor) (n = 3). **P < 0.01, vs. C16 ceramide. (C) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the C16 ceramide + Darapladib group than in the C16 ceramide group. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bar: 100 μm. (D) Western blot analysis of the expression levels of proteins associated with the classical NLRP3 pyroptosis pathway in BV2 cells after treatment with siCerS5 or Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01 (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-terminal GSDMD; Iba1: ionized calcium binding adaptor molecule 1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Article Snippet: The mice were randomly assigned to one of five groups (10 mice per group): (1) Sham group, with no SCI induced after opening the vertebral plate; (2) SCI group, with no intrathecal injection after striking the spinal cord; (3) SCI + si.CerS5 group, which were injected with 10 nmol CerS5 siRNA (si.CerS5) (synthesized by GenePharm, Shanghai, China; Table 1) intrathecally around the notch immediately after contusion; (4) SCI + si.NC group, which were injected intrathecally with si.NC (10 nmol) (synthesized by GenePharm, Shanghai, China; Table 1) around the notch immediately after contusion; (5) SCI + Darapladib group, which were injected intrathecally with Darapladib (a Pla2g7 inhibitor, 10 mg/kg, TargetMol, T6109, Boston, MA, USA) around the notch immediately after contusion; and (6) SCI + Vehicle group, which were injected intrathecally with vehicle (10% dimethylsulfoxide, 40% polyethylene glycol 300, 5% Tween-80, and 45% phosphate-buffered saline) around the notch immediately after contusion.

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Immunofluorescence, Staining, Comparison, Binding Assay

    Figure 8 ｜Darapladib inhibits microglial pyroptosis in the spinal cord after SCI. (A) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells in the SCI and Sham groups after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the SCI + Darapladib group compared with the SCI and SCI + Vehicle groups. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bars: 100 μm (upper); 20 μm (lower). (B) Western blot analysis of the expression levels of Pla2g7 and proteins associated with the classical NLRP3 pyroptosis pathway in the SCI and Sham groups after treatment with Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, vs. SCI group (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-term gasdermin D; IL: interleukin; NLRP3: NOD-like receptor thermal protein domain associated protein 3; Pla2g7: phospholipase a2 group VII; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Journal: Neural Regeneration Research

    Article Title: Inhibiting ceramide synthase 5 expression in microglia decreases neuroinflammation after spinal cord injury

    doi: 10.4103/nrr.nrr-d-23-01933

    Figure Lengend Snippet: Figure 8 ｜Darapladib inhibits microglial pyroptosis in the spinal cord after SCI. (A) Representative examples of immunofluorescence staining images used to quantify GSDMD+Iba1+ cells in the SCI and Sham groups after treatment with Darapladib (n = 5). There were significantly fewer GSDMD+Iba1+ cells in the SCI + Darapladib group compared with the SCI and SCI + Vehicle groups. Iba1, green, CoraLite 488; GSDMD, red, CoraLite 594; DAPI, blue. Scale bars: 100 μm (upper); 20 μm (lower). (B) Western blot analysis of the expression levels of Pla2g7 and proteins associated with the classical NLRP3 pyroptosis pathway in the SCI and Sham groups after treatment with Darapladib (n = 3). Data are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, vs. SCI group (one-way analysis of variance followed by Tukey’s multiple comparison test). ASC: Apoptosis associated speck like protein containing CARD; CerS: ceramide synthase; DAPI: 4′,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSDMD: gasdermin D; GSDMD-N: N-term gasdermin D; IL: interleukin; NLRP3: NOD-like receptor thermal protein domain associated protein 3; Pla2g7: phospholipase a2 group VII; SCI: spinal cord injury; si.CerS5: CerS5 siRNA.

    Article Snippet: The mice were randomly assigned to one of five groups (10 mice per group): (1) Sham group, with no SCI induced after opening the vertebral plate; (2) SCI group, with no intrathecal injection after striking the spinal cord; (3) SCI + si.CerS5 group, which were injected with 10 nmol CerS5 siRNA (si.CerS5) (synthesized by GenePharm, Shanghai, China; Table 1) intrathecally around the notch immediately after contusion; (4) SCI + si.NC group, which were injected intrathecally with si.NC (10 nmol) (synthesized by GenePharm, Shanghai, China; Table 1) around the notch immediately after contusion; (5) SCI + Darapladib group, which were injected intrathecally with Darapladib (a Pla2g7 inhibitor, 10 mg/kg, TargetMol, T6109, Boston, MA, USA) around the notch immediately after contusion; and (6) SCI + Vehicle group, which were injected intrathecally with vehicle (10% dimethylsulfoxide, 40% polyethylene glycol 300, 5% Tween-80, and 45% phosphate-buffered saline) around the notch immediately after contusion.

    Techniques: Immunofluorescence, Staining, Western Blot, Expressing, Comparison